MAY 13, 2020 3:44 PM PDT

Drug Targets Off Episodes of Parkinson

WRITTEN BY: Nouran Amin

A novel drug was approved by the FDA to target the “off” episodes of Parkinson disease. The drug is referred to as ‘Ongentys’ which is a catechol-o-methyltransferase (COMT) inhibitor that when combined with another drug improves treatment efficacy. In other words, Ongentys works with levodopa to increase more dopamine entry into the brain.

Learn more about Parkinson:

Dopamine is brain fuel that stimulates normal movements and decreases symptoms associated with Parkinson.

Learn more about dopamine:

Some adverse effects associated with Ongentys use includes abnormal dreams, headaches, sleep challenges, hallucinations, and low blood pressure. Although some complications, such as dyskinesia (involuntary movements), is related to levodopa boost rather than Ongentys alone.

Source: MichaelJFox.org

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 19, 2020
Cancer
Testing the Toxicity of CDK Inhibitors and Radiotherapy
AUG 19, 2020
Testing the Toxicity of CDK Inhibitors and Radiotherapy
Drug targets often focus on one thing, inhibiting or activating some critical function in a cell. Cancer drugs are no di ...
AUG 24, 2020
Neuroscience
Researchers Crowdfund $30 Million for Psychedelic Therapy for PTSD
AUG 24, 2020
Researchers Crowdfund $30 Million for Psychedelic Therapy for PTSD
In a historic feat, the Multidisciplinary Association for Psychedelic Studies (MAPS) has raised $30 million to complete ...
SEP 11, 2020
Drug Discovery & Development
Single Injection Sends Type 2 Diabetes into Remission
SEP 11, 2020
Single Injection Sends Type 2 Diabetes into Remission
Type 2 diabetes affects around 10% of people in the US. Although there is no cure for it, there are some well-known meth ...
SEP 07, 2020
Drug Discovery & Development
Improving Antirejection Medications in Heart Transplant
SEP 07, 2020
Improving Antirejection Medications in Heart Transplant
Placing patients on anti-rejection drugs is reality for all heart transplant patients. As such, recent research at Johns ...
SEP 20, 2020
Drug Discovery & Development
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
SEP 20, 2020
Cholesterol-Lowering Drugs Reduce The Severity of COVID-19
Almost a year into the beginnings of the COVID-19 pandemic and we still do not have a Food and Drug Administration (FDA) ...
OCT 13, 2020
Immunology
Early Tips For Cell & Gene Therapy Regulatory Compliance
OCT 13, 2020
Early Tips For Cell & Gene Therapy Regulatory Compliance
Cell and gene therapies hold great promise for improved health outcomes. Now is the time to advance life-saving research ...
Loading Comments...